Browse All

Current Filters

CLEAR FILTER x

TITLE

Real-world-data on Ofatumumab as First-line Treatment in Early RMS (AIOLOS study)

Author:Nelles, Gereon   Pfeuffer, Steffen   Wagner, Carola   

Session Name:P7: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1  

Topic:Multiple Sclerosis  

Program Number:P7.013  

Author Institution:Neuromed-Campus, Cologne, Germany  University Hospital Giessen, Giessen, Germany  Novartis Pharma GmbH, Nuremberg, Germany  

Longer-term (up to 6 Years) Efficacy and Safety of Ofatumumab in People with Non-highly Active MS Early in the Disease Course

Author:Ziemssen, Tjalf   Schuh, Katrin   Hentschke, Christian   Nelles, Gereon   

Session Name:P11: Multiple Sclerosis: Clinical and Translational Research in MS 1  

Topic:Multiple Sclerosis  

Program Number:P11.003  

Author Institution:University Clinic Carl-Gustav Carus, Dresden, Germany  Novartis Pharma GmbH, Nuremberg, Germany  Neuromed-Campus, Cologne, Germany